Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicOryx
- Development stage
- Phase 1
- Lead developer
- Oryx
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
MicOryx is an investigational therapeutic cancer vaccine developed by ORYX in collaboration with researchers at the University of Heidelberg. It is specifically designed for the treatment and prevention of cancers characterized by DNA mismatch repair (MMR) deficiency, such as colorectal cancer associated with Lynch syndrome. The vaccine is a trivalent formulation consisting of three synthetic frameshift peptide (FSP) neoantigens derived from recurrent mutations in the *AIM2*, *HT001* (also known as *ASTE1*), and *TAF1B* genes. These mutations are highly prevalent in MMR-deficient tumors due to microsatellite instability. Formulated with the adjuvant Montanide ISA-51 VG to enhance immunogenicity, MicOryx aims to stimulate the patient's immune system to mount both cellular (T-cell) and humoral (antibody) responses against cancer cells expressing these neoantigens. Clinical data from Phase I/IIa trials have demonstrated that the vaccine is well-tolerated and capable of inducing specific immune responses in patients with a history of dMMR colorectal cancer.
- Brand names
- MicOryx
- Other names
- FSP neoantigen vaccineFrameshift peptide neoantigen vaccine
02
Targets
Asteroid structure-specific endonuclease 1 frameshift peptideAIM2 (Absent in melanoma 2)
Beyond the preview
Go deeper on MicOryx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicOryx.